Literature DB >> 15479683

Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

A Sturm1, A Z A Leite, S Danese, K A Krivacic, G A West, S Mohr, J W Jacobberger, C Fiocchi.   

Abstract

BACKGROUND: Different abnormalities of T cell effector function distinguish Crohn's disease (CD) from ulcerative colitis (UC). Because cell cycling determines effector function, pathogenic events in CD and UC may depend on cell cycle changes unique to each condition.
METHODS: Cell cycle kinetics, cycle regulatory molecule expression, apoptosis, caspase and telomerase activity, and cellular expansion were evaluated in CD2 and CD3 activated control, CD, and UC lamina propria T cells.
RESULTS: Compared with normal cells, CD T cells cycle faster, express increased phosphorylated Rb and decreased phosphorylated p53 levels, display less caspase activity but more telomerase activity, die less, and undergo vigorous cellular expansion. In contrast, UC T cells cycle slower, express normal levels of phosphorylated Rb and p53, display more caspase activity but have no telomerase activity, die more, and have a limited capacity to expand.
CONCLUSIONS: T cell cycle abnormalities in CD indicate a state of hyperreactivity compatible with loss of tolerance, but a hyporeactive state compatible with anergy in UC. Thus distinct and divergent T cell cycle characteristics underlie the pathogenesis of the two main forms of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479683      PMCID: PMC1774268          DOI: 10.1136/gut.2003.033613

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  70 in total

Review 1.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

2.  Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis.

Authors:  M M Maurice; H Nakamura; E A van der Voort; A I van Vliet; F J Staal; P P Tak; F C Breedveld; C L Verweij
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

3.  Intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis, and controls.

Authors:  K Kusugami; K R Youngman; G A West; C Fiocchi
Journal:  Gastroenterology       Date:  1989-07       Impact factor: 22.682

4.  Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.

Authors:  R Duchmann; E Schmitt; P Knolle; K H Meyer zum Büschenfelde; M Neurath
Journal:  Eur J Immunol       Date:  1996-04       Impact factor: 5.532

5.  Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity.

Authors:  G A West; T Matsuura; A D Levine; J S Klein; C Fiocchi
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

Review 6.  Advances in intestinal T-cell development and function.

Authors:  J R Klein
Journal:  Immunol Today       Date:  1995-07

7.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

8.  Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.

Authors:  I J Fuss; M Neurath; M Boirivant; J S Klein; C de la Motte; S A Strong; C Fiocchi; W Strober
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

9.  Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers.

Authors:  S Fais; M R Capobianchi; F Pallone; P Di Marco; M Boirivant; F Dianzani; A Torsoli
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

10.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more
  22 in total

Review 1.  T cell apoptosis and inflammatory bowel disease.

Authors:  M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 2.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

3.  Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease.

Authors:  J N Gordon; T T MacDonald
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 4.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

Authors:  J Mudter; M F Neurath
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

5.  Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

Authors:  A Grabig; D Paclik; C Guzy; A Dankof; D C Baumgart; J Erckenbrecht; B Raupach; U Sonnenborn; J Eckert; R R Schumann; B Wiedenmann; A U Dignass; A Sturm
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro.

Authors:  Claudia Guzy; Anja Schirbel; Daniela Paclik; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  Eur J Nutr       Date:  2008-11-08       Impact factor: 5.614

7.  Angiogenesis blockade as a new therapeutic approach to experimental colitis.

Authors:  Silvio Danese; Miquel Sans; David M Spencer; Ivy Beck; Fernando Doñate; Marian L Plunkett; Carol de la Motte; Raymond Redline; David E Shaw; Alan D Levine; Andrew P Mazar; Claudio Fiocchi
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 8.  Etiopathogenesis of inflammatory bowel diseases.

Authors:  Silvio Danese; Claudio Fiocchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

9.  Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease.

Authors:  Heitor S P de Souza; Gail A West; Nancy Rebert; Carol de la Motte; Judy Drazba; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2012-06-26       Impact factor: 22.682

10.  Role of DOR-β-arrestin1-Bcl2 signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis.

Authors:  Pi-Qi Zhou; Heng Fan; Hui Hu; Qing Tang; Xing-Xing Liu; Li-Juan Zhang; Min Zhong; Zhe-Xing Shou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.